Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
April 20, 2018 08:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and...
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
April 02, 2018 08:15 ET
|
Abeona Therapeutics Inc.
Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare diseases Tim Miller, Ph.D. continues as president and assumes chief...
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease
February 12, 2018 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Management to Present at Multiple Conferences in November
November 13, 2017 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies
October 16, 2017 08:26 ET
|
Abeona Therapeutics Inc.
Nine global foundations collaborate to grant $13.85 million for the continued advancement of lead Sanfilippo gene therapy programsCompany receives infusion of an additional $5 million from exercise of...
Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
October 11, 2017 08:19 ET
|
Abeona Therapeutics Inc
ABO-102 Patients Enrolled in Cohort 3 at 3E13 vg/kgAccelerated enrollments begin with first Patient Enrolled at clinical site in Australia; Patient Screening at Spain site underwayDay 30 results...
Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa
October 06, 2017 08:25 ET
|
Abeona Therapeutics Inc
--Demonstrated durable and significant reduction of underlying disease pathology across multiple clinical measures in Cohort 1 (n=3) compared to controls (n=8-12) --Systemic Biopotency demonstrated...
Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102
September 28, 2017 08:32 ET
|
Abeona Therapeutics Inc
--Strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation --Phillip B. Maples, Ph.D., to lead Abeona manufacturing, as VP of Therapeutics...
Abeona Therapeutics Announces Upcoming Conference Participation
September 22, 2017 08:45 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene...
Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A
August 16, 2017 09:25 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies...